24.2 C
Sunday, October 25, 2020

CEPI, CSL to fund University of Queensland’s Covid-19 vaccine

Must read

Penrith lock Isaah Yeo has helped build a successful breeding ground at St Johns College in Dubbo

Humble Penrith lock Isaah Yeo isn’t big on self-praise as he prefers to let his actions do the talking, but he is a...

NRLW: Inspirational Trent Robinson speech revs up Sydney Roosters

An inspirational Trent Robinson speech has the Sydney Roosters NRLW side primed to defy the odds and beat back-to-back premiers Brisbane for the...
The Indian Telegraphhttps://theindiantelegraph.com.au/
Established in 2007, The Indian Telegraph is a multi award winning digital media company based in Australia.

Drugmaker CSL Ltd., the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland on Friday announced a partnership to accelerate the development, manufacture and distribution of a Covid-19 vaccine candidate.

Most recently, early preclinical results of the University of Queensland Covid-19 vaccine candidate showed that it produced high levels of antibodies that can neutralise the virus.

The initial clinical trial of the vaccine will begin next month in Brisbane.

As part of the new agreement, CEPI and CSL will fund the development and manufacture of UQ’s “molecular clamp” enabled vaccine for Covid-19.

Funding contributions will be used to provide support for the pending phase 1 safety study being led by UQ followed by subsequent late stage clinical trials, and industrial-scale manufacturing to allow the production of potentially millions of doses a year, should the product be approved.

The initial phase of large-scale production of the vaccine is planned to take place at CSL’s biotech manufacturing facilities in Melbourne.

The UQ vaccine is expected to be available in 2021 should clinical trials be successful.

CSL anticipates that the production technology can be scaled to produce up to 100 million doses towards the end of next year.

The company said that it would also subcontract other global manufacturers to increase the number of doses that can be produced and broaden the geographical distribution of vaccine production.

“This significant partnership between CEPI, UQ and CSL is an important milestone in the development of UQ’s promising COVID-19 vaccine candidate,” Richard Hatchett, CEO of CEPI, said in a statement.

“The partnership will enable the rapid development of the vaccine candidate through clinical trials, and by investing in large-scale manufacturing capacity now, we can reduce the time needed to deliver millions of doses of the UQ vaccine to those who need them most if it proves to be safe and effective.”

CEPI entered into a framework agreement with UQ in January 2019 to provide up to $10.6 million to develop a rapid response “molecular clamp” vaccine platform, a transformative technology patented by UniQuest, UQ’s technology transfer company that enables rapid vaccine design and production against outbreak viral pathogens.

In January 2020, CEPI expanded its partnership with UQ to use their rapid response molecular clamp vaccine platform to produce a vaccine candidate for Covid-19.

UQ is now aiming to take the vaccine candidate in to a phase 1 clinical trial in July.

“CSL will contribute to UQ’s promising vaccine with our proprietary adjuvant, MF59, made by Seqirus, along with expertise in process science and scale-up from our Australian facilities, managing advanced clinical trials and the large-scale manufacture of the recombinant vaccine,” said Andrew Cuthbertson, CSL’s Chief Scientific Officer.

“Should trials be successful, this vaccine holds the potential to provide protection against this urgent public health emergency for Australians and those around the world vulnerable to this devastating virus.”

Latest article

Crown on line casino: AUSTRAC ticked off on on line casino junkets in 2017

The monetary crimes watchdog in 2017 mentioned junket partnerships with Australian casinos had been compliant with anti-money laundering legal guidelines, regardless of detailed...

Scam 1992 Review Watch Online

Hansal Mehta's Scam 1992 is the story of the rise and fall of the Big Bull Of Dalal Street, Harshad Mehta.

Harshad Mehta Scam 1992

Who is Harshad Mehta? Harshad Mehta was a well known Indian stockbroker, who was known for his wealth and was charged...

Melbourne COVID-19 restrictions: Companies slam Dan Andrews’ delay

Companies have slammed Daniel Andrews’ “cautious pause” on easing restrictions, after a hoped-for announcement that retail and hospitality may start opening was delayed...

Coronavirus Victoria: Scott Morrison criticises Dan Andrews’ continued lockdown

Prime Minister Scott Morrison has lashed out at Victorian Premier Daniel Andrews over his decision not to lift coronavirus restrictions, keeping the vast...